Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-1037 in Cystic Fibrosis
NCT02343445Phase 2Completed
- Sponsor
- Parion Sciences
- Start
- Apr 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of idrevloride in cystic fibrosis (CF) (4 arms), sponsored by Parion Sciences. Primary endpoints: Number of adverse events at Day 15 and Change in forced expiratory volume in one second (FEV1) from predosing to 1 hour post dosing. Started Apr 2015; status: completed.
02
Drugs
idrevloride
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02343445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343445.